drugset / Trial / NCT04112160

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

NCT04112160

Phase 2 Completed 125 enrolled University of Texas Southwestern Medical Center
RandomizedSingle-groupQuadruple-blindPrevention

Summary

This is a prospective randomized double-blind controlled trial assessing the benefits of intramuscular ketorolac before or immediately after office ureteral stent removal.

Timeline

Start
2018-06-28
Primary completion
2019-06-30
Completion
2019-08-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Other / unclassified 30 mg Intramuscular

Indications